ARCALIS Inc. is pleased to announce that Kazuyuki Nakashima, General Manager of the Development Division, will present and join a panel discussion at the 22nd Regulatory Science Symposium, to be held on February 10, 2026, at Hitotsubashi Hall in Tokyo.

The symposium, held under the theme “Perspectives on Quality Evaluation of mRNA Therapeutics,” provides a forum for sharing the latest insights into quality and regulatory science related to mRNA medicines.

Event Overview

• Date & Time: February 10, 2026 (Tuesday), 1:00 PM – 4:35 PM (JST)
• Venue: Hitotsubashi Hall
   (Academic General Center, 2-1-2 Hitotsubashi, Chiyoda-ku, Tokyo, Japan)
• Organizer: Regulatory Science Division, Nucleic Acids Therapeutics Society of Japan

▶ Event details and registration: https://www.natsj.jp/event

▶ Abstracts are available here: ：kakusanRSsymp22.pdf　

Lecture and Panel Discussion

As a part of the symposium program, Mr. Nakashima will give a presentation titled
 “Quality Control Strategies and Challenges for mRNA Therapeutics.”

He will also join a panel discussion alongside experts from industry, academia, and regulatory authorities who are at the forefront of the mRNA therapeutics field. The discussion is expected to cover a broad range of important topics related to the quality evaluation of mRNA medicines.